The global Gene-based Advanced Therapy Medicinal market size was valued at US$ 14080 million in 2024 and is forecast to a readjusted size of USD 48880 million by 2031 with a CAGR of 19.7% during review period.
Gene Delivery System or Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient"s cells instead of using drugs or surgery.
The advanced therapy based on gene market is driven by the potential to revolutionize healthcare by offering personalized and targeted treatments for genetic disorders and other diseases. Advanced therapy based on gene includes gene therapy, cell therapy, and gene editing techniques, which aim to modify or replace faulty genes to treat or cure diseases at the genetic level. The rise in the understanding of genetic mechanisms and advancements in biotechnology and genetic engineering contribute to market growth as these therapies hold promise for previously untreatable conditions. Moreover, increasing investment in research and clinical trials and the support from regulatory agencies for accelerated approval further boost the development and commercialization of advanced gene therapies. However, the market also faces challenges, including the complexity of manufacturing and delivering gene-based therapies, safety concerns related to viral vectors and off-target effects in gene editing, and high treatment costs. Additionally, addressing regulatory requirements and ensuring accessibility and affordability of advanced gene therapies can pose obstacles for broader adoption. To succeed, companies must focus on research and development to advance the safety and efficacy of gene-based therapies, collaborate with healthcare stakeholders to build robust infrastructure, and address the challenges to fully realize the transformative potential of advanced therapy based on gene in modern medicine.
This report is a detailed and comprehensive analysis for global Gene-based Advanced Therapy Medicinal market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Gene-based Advanced Therapy Medicinal market size and forecasts, in consumption value ($ Million), 2020-2031
Global Gene-based Advanced Therapy Medicinal market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Gene-based Advanced Therapy Medicinal market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Gene-based Advanced Therapy Medicinal market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gene-based Advanced Therapy Medicinal
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Gene-based Advanced Therapy Medicinal market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen, Spark Therapeutics, Akcea Therapeutics, Sunway Biotech, SIBIONO, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Gene-based Advanced Therapy Medicinal market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Viral Gene Delivery System
Non-viral Gene Delivery System
麻豆原创 segment by Application
Neurological Diseases
Cancer
Other
麻豆原创 segment by players, this report covers
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Gene-based Advanced Therapy Medicinal product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Gene-based Advanced Therapy Medicinal, with revenue, gross margin, and global market share of Gene-based Advanced Therapy Medicinal from 2020 to 2025.
Chapter 3, the Gene-based Advanced Therapy Medicinal competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Gene-based Advanced Therapy Medicinal market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Gene-based Advanced Therapy Medicinal.
Chapter 13, to describe Gene-based Advanced Therapy Medicinal research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Gene-based Advanced Therapy Medicinal by Type
1.3.1 Overview: Global Gene-based Advanced Therapy Medicinal 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Gene-based Advanced Therapy Medicinal Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Viral Gene Delivery System
1.3.4 Non-viral Gene Delivery System
1.4 Global Gene-based Advanced Therapy Medicinal 麻豆原创 by Application
1.4.1 Overview: Global Gene-based Advanced Therapy Medicinal 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Neurological Diseases
1.4.3 Cancer
1.4.4 Other
1.5 Global Gene-based Advanced Therapy Medicinal 麻豆原创 Size & Forecast
1.6 Global Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast by Region
1.6.1 Global Gene-based Advanced Therapy Medicinal 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Gene-based Advanced Therapy Medicinal 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Biogen
2.1.1 Biogen Details
2.1.2 Biogen Major Business
2.1.3 Biogen Gene-based Advanced Therapy Medicinal Product and Solutions
2.1.4 Biogen Gene-based Advanced Therapy Medicinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Biogen Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Gene-based Advanced Therapy Medicinal Product and Solutions
2.2.4 Novartis Gene-based Advanced Therapy Medicinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Gilead Sciences
2.3.1 Gilead Sciences Details
2.3.2 Gilead Sciences Major Business
2.3.3 Gilead Sciences Gene-based Advanced Therapy Medicinal Product and Solutions
2.3.4 Gilead Sciences Gene-based Advanced Therapy Medicinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Gilead Sciences Recent Developments and Future Plans
2.4 Sarepta Therapeutics
2.4.1 Sarepta Therapeutics Details
2.4.2 Sarepta Therapeutics Major Business
2.4.3 Sarepta Therapeutics Gene-based Advanced Therapy Medicinal Product and Solutions
2.4.4 Sarepta Therapeutics Gene-based Advanced Therapy Medicinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Sarepta Therapeutics Recent Developments and Future Plans
2.5 Alnylam Pharmaceuticals
2.5.1 Alnylam Pharmaceuticals Details
2.5.2 Alnylam Pharmaceuticals Major Business
2.5.3 Alnylam Pharmaceuticals Gene-based Advanced Therapy Medicinal Product and Solutions
2.5.4 Alnylam Pharmaceuticals Gene-based Advanced Therapy Medicinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
2.6 Amgen
2.6.1 Amgen Details
2.6.2 Amgen Major Business
2.6.3 Amgen Gene-based Advanced Therapy Medicinal Product and Solutions
2.6.4 Amgen Gene-based Advanced Therapy Medicinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Amgen Recent Developments and Future Plans
2.7 Spark Therapeutics
2.7.1 Spark Therapeutics Details
2.7.2 Spark Therapeutics Major Business
2.7.3 Spark Therapeutics Gene-based Advanced Therapy Medicinal Product and Solutions
2.7.4 Spark Therapeutics Gene-based Advanced Therapy Medicinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Spark Therapeutics Recent Developments and Future Plans
2.8 Akcea Therapeutics
2.8.1 Akcea Therapeutics Details
2.8.2 Akcea Therapeutics Major Business
2.8.3 Akcea Therapeutics Gene-based Advanced Therapy Medicinal Product and Solutions
2.8.4 Akcea Therapeutics Gene-based Advanced Therapy Medicinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Akcea Therapeutics Recent Developments and Future Plans
2.9 Sunway Biotech
2.9.1 Sunway Biotech Details
2.9.2 Sunway Biotech Major Business
2.9.3 Sunway Biotech Gene-based Advanced Therapy Medicinal Product and Solutions
2.9.4 Sunway Biotech Gene-based Advanced Therapy Medicinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Sunway Biotech Recent Developments and Future Plans
2.10 SIBIONO
2.10.1 SIBIONO Details
2.10.2 SIBIONO Major Business
2.10.3 SIBIONO Gene-based Advanced Therapy Medicinal Product and Solutions
2.10.4 SIBIONO Gene-based Advanced Therapy Medicinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 SIBIONO Recent Developments and Future Plans
2.11 AnGes
2.11.1 AnGes Details
2.11.2 AnGes Major Business
2.11.3 AnGes Gene-based Advanced Therapy Medicinal Product and Solutions
2.11.4 AnGes Gene-based Advanced Therapy Medicinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 AnGes Recent Developments and Future Plans
2.12 Orchard Therapeutics
2.12.1 Orchard Therapeutics Details
2.12.2 Orchard Therapeutics Major Business
2.12.3 Orchard Therapeutics Gene-based Advanced Therapy Medicinal Product and Solutions
2.12.4 Orchard Therapeutics Gene-based Advanced Therapy Medicinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Orchard Therapeutics Recent Developments and Future Plans
2.13 Human Stem Cells Institute
2.13.1 Human Stem Cells Institute Details
2.13.2 Human Stem Cells Institute Major Business
2.13.3 Human Stem Cells Institute Gene-based Advanced Therapy Medicinal Product and Solutions
2.13.4 Human Stem Cells Institute Gene-based Advanced Therapy Medicinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Human Stem Cells Institute Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Gene-based Advanced Therapy Medicinal Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Gene-based Advanced Therapy Medicinal by Company Revenue
3.2.2 Top 3 Gene-based Advanced Therapy Medicinal Players 麻豆原创 Share in 2024
3.2.3 Top 6 Gene-based Advanced Therapy Medicinal Players 麻豆原创 Share in 2024
3.3 Gene-based Advanced Therapy Medicinal 麻豆原创: Overall Company Footprint Analysis
3.3.1 Gene-based Advanced Therapy Medicinal 麻豆原创: Region Footprint
3.3.2 Gene-based Advanced Therapy Medicinal 麻豆原创: Company Product Type Footprint
3.3.3 Gene-based Advanced Therapy Medicinal 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Gene-based Advanced Therapy Medicinal Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Gene-based Advanced Therapy Medicinal 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Gene-based Advanced Therapy Medicinal Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Gene-based Advanced Therapy Medicinal 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Gene-based Advanced Therapy Medicinal Consumption Value by Type (2020-2031)
6.2 North America Gene-based Advanced Therapy Medicinal 麻豆原创 Size by Application (2020-2031)
6.3 North America Gene-based Advanced Therapy Medicinal 麻豆原创 Size by Country
6.3.1 North America Gene-based Advanced Therapy Medicinal Consumption Value by Country (2020-2031)
6.3.2 United States Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Gene-based Advanced Therapy Medicinal Consumption Value by Type (2020-2031)
7.2 Europe Gene-based Advanced Therapy Medicinal Consumption Value by Application (2020-2031)
7.3 Europe Gene-based Advanced Therapy Medicinal 麻豆原创 Size by Country
7.3.1 Europe Gene-based Advanced Therapy Medicinal Consumption Value by Country (2020-2031)
7.3.2 Germany Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Gene-based Advanced Therapy Medicinal Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Gene-based Advanced Therapy Medicinal Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Gene-based Advanced Therapy Medicinal 麻豆原创 Size by Region
8.3.1 Asia-Pacific Gene-based Advanced Therapy Medicinal Consumption Value by Region (2020-2031)
8.3.2 China Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Gene-based Advanced Therapy Medicinal Consumption Value by Type (2020-2031)
9.2 South America Gene-based Advanced Therapy Medicinal Consumption Value by Application (2020-2031)
9.3 South America Gene-based Advanced Therapy Medicinal 麻豆原创 Size by Country
9.3.1 South America Gene-based Advanced Therapy Medicinal Consumption Value by Country (2020-2031)
9.3.2 Brazil Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Gene-based Advanced Therapy Medicinal Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Gene-based Advanced Therapy Medicinal Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Gene-based Advanced Therapy Medicinal 麻豆原创 Size by Country
10.3.1 Middle East & Africa Gene-based Advanced Therapy Medicinal Consumption Value by Country (2020-2031)
10.3.2 Turkey Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Gene-based Advanced Therapy Medicinal 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Gene-based Advanced Therapy Medicinal 麻豆原创 Drivers
11.2 Gene-based Advanced Therapy Medicinal 麻豆原创 Restraints
11.3 Gene-based Advanced Therapy Medicinal Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Gene-based Advanced Therapy Medicinal Industry Chain
12.2 Gene-based Advanced Therapy Medicinal Upstream Analysis
12.3 Gene-based Advanced Therapy Medicinal Midstream Analysis
12.4 Gene-based Advanced Therapy Medicinal Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
听
听
*If Applicable.
